Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lung adenocarcinoma with malignant serous effusions: A comprehensive clinicopathologic, molecular, and outcome analysis.

Cancer cytopathology·2026

Same author

Performance of Statistical and Machine Learning Risk Prediction Models for Advanced Breast Cancers.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026

Same author

Regression methods for cost-effectiveness analysis with different censoring times or terminating events for survival time and costs.

Biometrics·2026

Same author

Systemic AL (λ) Amyloidosis Discovered After Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy for Resectable NSCLC: Case Report.

Respirology case reports·2026

Same author

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.

Nature medicine·2026

Same author

Label-free fluorescence lifetime imaging for rapid discrimination of high-grade prostate cancer in fresh biopsy cores: a feasibility study.

Journal of biomedical optics·2026

Search research articles

Related Experiment Video

Updated: Aug 10, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Labyrinthin Expression Is Associated with Poor Prognosis in Patients with Non-Small-Cell Lung Cancer.

Weijie Ma^1,2, Jie Zeng¹, Dennis J Montoya^3,4

¹Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA 95817, USA.

|February 11, 2023

Summary

Labyrinthin (LAB) is highly expressed in most non-small-cell lung cancers (NSCLC). High LAB expression correlates with poorer survival and advanced disease, identifying it as a prognostic factor for NSCLC patients.

Keywords:

RNA sequencing TCGA labyrinthin lung adenocarcinoma lung squamous cell carcinoma non-small-cell lung cancer prognosis tissue microarray

More Related Videos

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Related Experiment Videos

Last Updated: Aug 10, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Area of Science:

Oncology
Molecular Pathology

Background:

Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide.
Identifying novel prognostic biomarkers and therapeutic targets is crucial for improving patient outcomes.

Purpose of the Study:

To investigate the expression of Labyrinthin (LAB) in NSCLC.
To evaluate the association of LAB expression with clinical characteristics and patient survival.
To assess LAB as a potential biomarker for patient selection in clinical trials.

Main Methods:

Immunohistochemistry (IHC) on tissue microarrays from 256 NSCLC samples.
Propensity-score-weighted survival analyses (Kaplan-Meier and Cox models).
Analysis of LAB mRNA expression in The Cancer Genome Atlas (TCGA) datasets for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).

Main Results:

LAB protein expression was detected in 81.3% of NSCLC cases, present in both LUAD and LUSC.
Positive LAB IHC expression was significantly associated with poor overall survival (HR = 3.56) and higher tumor grade/metastasis.
LAB expression was confirmed as an independent prognostic factor for NSCLC.
LAB mRNA levels were elevated in primary and advanced LUAD tumors and correlated with poorer survival, but not significantly in LUSC.

Conclusions:

Labyrinthin is frequently expressed in NSCLC and serves as a significant independent prognostic biomarker.
LAB expression may guide patient stratification for targeted therapies, including the ongoing Phase I trial for LAB vaccines.